New weekly shot could fight deadly mould infections with fewer side effects
Disease control
Recruiting now
This Phase 2 trial tests whether a new drug called EL219 (Turletricin) is safe and effective for early treatment of invasive mould infections in people with weakened immune systems, such as those who have had a bone marrow transplant. About 60 participants will receive either EL2…
Phase: PHASE2 • Sponsor: Elion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC